Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Etoposide × NET × Clear all
NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡